An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment - Peterson, L.; Marbury, T.; Marier, J.; Laliberte, K. (Journal of clinical pharmacy and therapeutics, 2013)
Keywords: Adult; Antihypertensive Agents - adverse effects; Antihypertensive Agents - pharmacokinetics; Area Under Curve; Biological and medical sciences; Body Mass Index; Body Weight - physiology; Chromatography, High Pressure Liquid; clinical trials; Cohort Studies; Delayed-Action Preparations; Epoprostenol - adverse effects; Epoprostenol - analogs & derivatives; Epoprostenol - pharmacokinetics; Female; Gastroenterology. Liver. Pancreas. Abdomen; Half-Life; Healthy Volunteers; hepatic impairment; Humans; Liver Diseases - metabolism; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Other diseases. Semiology; pharmacokinetics; Pharmacology. Drug treatments; Pneumology; pulmonary arterial hypertension; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Tandem Mass Spectrometry; treprostinil; Diolamine; Human; Evaluation; Vasodilator agent; Prostaglandin I2; Respiratory disease; Cardiovascular disease; Hepatic disease; Artery; Pulmonary hypertension; hepatic impairment; Liver failure; Blood vessel; Treprostinil; Digestive diseases; Clinical trial; clinical trials; Circulatory system; Pharmacokinetics; pulmonary arterial hypertension; pharmacokinetics; treprostinil